Article
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
Cancer - 15 Jul 2014
Alvarado Yesid, Kantarjian Hagop M, Luthra Rajyalakshmi, Ravandi Farhad, Borthakur Gautam, Garcia-Manero Guillermo, Konopleva Marina, Estrov Zeev, Andreeff Michael, Cortes Jorge E
Abstract excerpt
BACKGROUND: FLT3-internal tandem duplication (ITD) mutations are found in approximately 30% of patients with acute myeloid leukemia (AML). FLT3 inhibitors have shown clinical activity in AML with FLT3-ITD, but responses are usually short-lived. METHODS: This study examined 69 FLT3-mutated patient...
Topics
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Benzothiazoles
- Carbazoles
- DNA Mutational Analysis
- Female
- Furans
- Humans
- Leukemia, Myeloid, Acute
- Male
- Medical Records
- Middle Aged